Roche's Challenge With Herceptin Gastric Cancer Claim Will Be Companion Dx Use

As with Herceptin in breast cancer, the drug is approved simultaneously with a companion diagnostic to measure HER2 levels in gastric cancer patients, but the use of the test is different.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet